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ABSTRACT 
 
The majority of new drugs registered at Health Global Market are not considered real innovations and due to their chemical structure similarity 
of reference’s group drug, they are known as “me-too”. These “me too” drugs usually has no additional therapeutic benefits but greatly 
increasing treatment cost. PURPOSE: To demonstrate the economic impact in Social Security budget by covering “me too” medicines. METHODS: 
An epidemiological-descriptive-analytical study was performed in order to analyze the burden of anti-hypertensive prescription from patients 
under coverage by Buenos Aires State Social Security (SS). Two types of medicines were compared: “pioneer/classic” or “me-too”. Variables 
considered were: medicine type, therapeutical group, global costs, burden for SS and for patients. RESULTS: From 185865 patients with 
hypertension treated; in 121748 of the cases the strategy was monotherapy while 64117 of them received at least two or more medicines. 
189714 were reference drugs while 64393 were considered “me-too”. In average, “me-too” drugs were 41.23% more expensive than classical 
treatment. The percentage covered by SS varies according to the medicines (between 45 to 51%) and patients must complete the amount of 
money remaining from their pockets. Paradoxically, the percentage covered by SS of some “me-too” were greater than coverage for most classic 
medications of each group. CONCLUSIONS: By only choosing the drug of reference from each therapeutical group with has proven effectiveness, 
the Social Security might increase the coverage to 100% of the cost of all anti-hypertensive treatment for all patients; and even that, still saving almost 2 
million dollars per year. 
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INTRODUCTION 
 
Pharmacological treatments became an important 
component of Health systems budgets, especially for the 
known as “high-cost medicines” that have captured the 
attention of health funders and are worrying health systems 
all over the world because of their risk of an economic 
bankruptcy 1. 
 
However, little has been focused on medicines that, although 
less expensive, could have a negative impact for the public 
finances of the health systems. This is the case of a group of 
medicines known as "me-too"2. Concerning this type of 
drugs, it could be said that the pharmaceutical industry 
makes an investment to develop medicines with identical 
mechanisms of action to a pioneer/reference pre-existing  
 
ISSN: 2250-1177          [234] 
 
 
 
 
drug from same therapeutical group, which has already 
proven to be an efficient treatment 3. It could then be argued 
that this type of drugs would be valuable to payers if they 
save costs 4. However, this situation is generally the reverse, 
since when a new therapeutic option appears in the market, 
it has a higher cost than the drugs previously available in the 
pharmacy 5. 
 
This situation occurs because, once these “me too” drugs are 
marketed, they must be installed among prescribers and 
patients, through promotional spending, delivery of free 
medical samples, initial price discounts, advertisements, 
events and conferences, all elements that are associated with 
large expenses that will be recovered once the new drug is 
installed among patients and doctors in order to potentially 
replace the pre-existing drug of the class group 6. 
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The problem is that this new drug is always placed the 
pharmaceutical market at a higher price than the reference 
medicine, increasing costs for both patients and the health 
systems 7. But the impact in the budgets of developing countries 
of the inclusion of these me-too drugs in their official list of 
medicines to be cover by public funders, is still uncertain 8. 
 
It is the purpose of this paper to determine the economic 
impact, for the Buenos Aires State Social Security (SS), of 
financing “me-too” drugs and to calculate the potential save 
of replacement the “me-too” option by the pioneer/ 
reference drug in each therapeutical group that already have 
demonstrated its efficacy, its safety and its suitability to treat 
a highly prevalent chronic disease like hypertension. 
 
METHODS 
 
Type of study 
 
The present work should be classified as an epidemiological-
descriptive study with an analytical stage. 
 
Population   
Patients enrolled for this study were Buenos Aires State So-
cial Security beneficiaries nucleated in IOMA (BA State SS), 
affected by hypertension disease that required 
pharmacological treatment. 
 
Inclusion and Exclusion Criteria of patients to the study 
 
For the present study, authors adopted the recommendations 
of the Eighth Joint National Committee for diagnosis and 
treat-ment of hypertension disease, in order to enroll 
patients in the analysis. 
 
Exclusion criteria were patients hospitalized at the time 
while the study was initiated, or patients were severe 
hypertension disease that need intravenous treatment. 
 
Period of study 
 
01/01/2017 to 31/12/2017 
 
Cost evaluation 
 
The cost of the medicines was considered as defined daily 
dose (DDD) for each patient treated. The prescription and 
drug delivery were extracted from SS annual ambulatory 
data-base. 
 
Statistical analysis 
 
In order to analyze the statistical significance of the 
experimental results between the different groups, the non-
parametric ANOVA test was used, provided p <0.05 as the 
limit of significance. 
 
RESULTS 
 
The number of patients with hypertension that demand 
coverage of treatment to the State Social Security IOMA 
during the period of study were 185865 patients; 121748 of 
them received only one anti-hypertensive drug while 64117 
received at least two or more medicines. The patient’s 
adherence to anti-hypertensive treatment was 40.5% in av-
erage for all medicines. Almost twenty different drugs were 
prescript in order to treat patients under SS-IOMA coverage 
(Figure 1). 
 
 
Figure 1: Anti-hypertensive medicines prescripted in Buenos Aires Social Security (SS) 
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ISSN: 2250-1177 [235]          CODEN (USA): JDDTAO 
Marin et al Journal of Drug Delivery & Therapeutics. 2020; 10(3-s):PageNo. 
 
While 189714 of the drugs prescript were pioneer/reference 
drugs, 64393 were classified as “me-too”. 
 
The description of the drug covered by SS is exposed in 
Table 1. 
 
   
 
 
 
Table 1: Characteristics of anti-hypertensive drugs covered 
Therapeutic Group Drug Nº 
patient 
treated 
Mean  
Price in 
Argentine 
market 
Expenses 
for IOMA 
% de 
covered 
P
io
n
e
er
 D
ru
g
 ACE inhibitor Enalapril 71145  134.80  66.00  48.9  
Beta Blockers   Atenolol  21392  206.80  77.37  37.4  
Angiotensin 
Receptor Blockers 
Losartan  41437  357.10  246.00  68.9  
Calcium Blockers  Amlodipine  30053  194.97  99.60  51.1  
Diuretics HClthiazide  23932  123.53  78.00  63.1  
Clortalidone  1782  59.94  22.64  37.7  
M
e
-T
o
o
 G
ru
g
 G
ro
u
p
 
ACE inhibitor Lisinopril  637  296.94  102.94  34.6  
Ramipril  552  374.84  182.03  48.5  
Beta Blockers   Metoprolol  924  294.55  163.97  55.6  
Sotalol  79  449.50  237.60  52.8  
Bisoprolol  25439  299.56  189.60  63.3  
Propranolol  2327  231.78  91.58  39.5  
Angiotensin 
Receptor Blockers 
Candesartan  3467  685.66  309.54  45.1  
Valsartan   15400  423.08  228.00  53.9  
Ibersartan  832  748.61  370.79  49.5  
Telmisartan  8213  930.47  411.6  44.2  
 Calcium Blockers Nifedipine  2101  443.21  235.73  53.2  
Diltiazem  4207  569.33  316.28  55.5  
Felodipine  215  525.08  266.71  50.8  
 
 
 
In average, “me-too” drugs were 41.23% more expensive than 
classical treatment. The percentage covered by SS varied 
according to the medicines prescribed and it was in average 
50.1% (range 37 to 68%). The patients had to complete the 
amount of money remaining from their own pockets. Para-
doxically, the percentage covered by SS for some “me-too” were 
greater than the percentage covered and paid for most classic 
medications of each group (table 1). 
 
 
 
Analysing in detail any of the therapeutical groups it is clear 
that although the patients were treated mostly with the 
pioneer medicine, the few people that consumed “me-too” 
drugs, has spent the same o even more money than the 
majority of the patients treated (Figure 2). 
 
 
 
 
 
Figure 2: Cost analysis for hypertension treatment with angiotensin receptor blockers (ARB)  
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By only choosing the drug of reference from each 
therapeutical group, the State Social Security could cover 
100% of the cost of all anti-hypertensive treatment and all  
 
patients even saving almost 2 million dollars per year just by 
taking that decision (Figure 3). 
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Figure 3: Market Price of Anti-Hypertensive Medications covered by SS-IOMA for the treatment of all patients 
(in millions of pesos) 
 
* IOMA real expense to cover all of their hypertensive patients with the drug chosen considering their current prescriptions during 
the period of the study; #Expense if IOMA replaced the me-too drug with the pioneer drug (average cost between existing com-
mercial brands in the market) + For pioneer drug it exists several trade mark options in Argentinean market. This calculation is 
made taking into account the cheapest option in the market 
 
DISCUSION 
 
WHO stands for the rational use of medicines that includes 
recommendations in order to guarantee efficacy, safety, ac-
cess and purchase of each drug at the lowest possible mar-
ket price 9,10. It is logical to think that paying more for the 
same outcome is irrational.  
It should be recognized that “me-too” drugs also demands 
many research and development resources from the phar-
maceutical industries by creating these new products that 
mainly are not differentiated from pre-existing drugs; efforts 
that could be focus in more usefull task that requires ugent 
attention. 11. 
 
So, if “me-too” drugs have the same mechanism of action and 
same outcomes that the pioneer/reference molecule of its 
therapeutical class group, it could be stand that the only goal 
of the pharmaceutical producers to develop molecules "me-
too" is either to create additional costs of product, or to split 
the market with new drug options that has new brand patent 
that must be respected by the sanitary and commer-cial 
authorities of the countries 12.   
Noteworthy, it is still unclear why these “me-too” drugs are 
allowed to be registered in different countries while they do not 
add benefits except for the profitability for Pharmaceu-tical 
Industry of being marketed at a higher price than the pre-
existing equivalent drugs. And even more, why the health 
system and the Social Security are paying for these type of 
drugs, when there are well known options at a lower price?   
It also should be discussed the fact that, although the profile 
of adverse effects are shared by all the drugs of a given ther-
apeutic group, it is also true that side effects of the pioneer 
drugs are already well known by doctors and patients due 
the longest period of time that these drugs has been placed 
in the market, in relation to the “ me-too ” option 13. Is  
 
 
reasonable to accept then, that the new formula might have 
unexpected side effects that could expose patients to 
unnecessary risks. 
 
Those authors that support the use of “me-too” drugs sus-
tain that these products provide more therapeutic options 
and enhance competition 2. But why do we need new drugs 
of the same class and the same mechanism of action to do 
the same things and to get similar clinical outcomes, but at a 
much higher price?. It is true that some of the “me too” 
options have some kinetic characteristics that may provide 
longer duration of the effect, but that is not the rule 14. 
 
The results obtained in the present research demonstrate that 
by only replacing “me-too” drugs by the pioneer medicine, the 
Social Security of Buenos Aires (SS-IOMA) may increase the 
treatment coverage up to a 100% without additional ex-penses 
for patients, and even saving money from its budget. 
 
The study also demonstrated that only 40% of the patients 
had adherence to treatment. Even if this topic is complexed 
and multi-factional 15, 16, and it is not an issue to be 
problematized in this paper, the data analysis lead us to 
think that if one of the causes that explains the lack of 
continuity in the treat-ments might be the pocket payment 
that patients must face, maybe if this payment obligation is 
exempted by installing a 100% coverage of the drugs by SS, 
then this percentage of adherence could be increased.   
CONCLUSION 
 
By taking the decision to replace "me-too" drugs for pioneer/ 
referral medicines it is possible to increase the Buenos Aires 
State Social Security treatment coverage from approximate-ly 
50% to 100%, avoiding the out-of-pocket payment by pa-tients; 
without affecting the quality of care or the outcome obtained 
from t reatments of patients affected by arterial 
 
ISSN: 2250-1177 [237]          CODEN (USA): JDDTAO 
Marin et al Journal of Drug Delivery & Therapeutics. 2020; 10(3-s):PageNo. 
 
hypertension. Only considering the standard treatment for 
their hypertensive patients, even increasing the coverage up 
to 100%, this measure allows obtaining a saving for the 
mentioned financier institution (SS) of almost two million 
dollars a year. 
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